Merck Revenue 2010-2023 | MRK

Merck annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Merck revenue for the quarter ending December 31, 2023 was $14.630B, a 5.78% increase year-over-year.
  • Merck revenue for the twelve months ending December 31, 2023 was $60.114B, a 1.4% increase year-over-year.
  • Merck annual revenue for 2023 was $60.115B, a 1.4% increase from 2022.
  • Merck annual revenue for 2022 was $59.283B, a 21.72% increase from 2021.
  • Merck annual revenue for 2021 was $48.704B, a 17.31% increase from 2020.
Merck Annual Revenue
(Millions of US $)
2023 $60,115
2022 $59,283
2021 $48,704
2020 $41,518
2019 $39,121
2018 $42,294
2017 $40,122
2016 $39,807
2015 $39,498
2014 $42,237
2013 $44,033
2012 $47,267
2011 $48,047
2010 $45,987
2009 $27,428
Merck Quarterly Revenue
(Millions of US $)
2023-12-31 $14,630
2023-09-30 $15,962
2023-06-30 $15,035
2023-03-31 $14,487
2022-12-31 $13,830
2022-09-30 $14,959
2022-06-30 $14,593
2022-03-31 $15,901
2021-12-31 $13,521
2021-09-30 $13,154
2021-06-30 $11,402
2021-03-31 $10,627
2020-12-31 $9,179
2020-09-30 $10,929
2020-06-30 $9,353
2020-03-31 $12,057
2019-12-31 $4,148
2019-09-30 $12,397
2019-06-30 $11,760
2019-03-31 $10,816
2018-12-31 $10,998
2018-09-30 $10,794
2018-06-30 $10,465
2018-03-31 $10,037
2017-12-31 $10,433
2017-09-30 $10,325
2017-06-30 $9,930
2017-03-31 $9,434
2016-12-31 $10,115
2016-09-30 $10,536
2016-06-30 $9,844
2016-03-31 $9,312
2015-12-31 $10,215
2015-09-30 $10,073
2015-06-30 $9,785
2015-03-31 $9,425
2014-12-31 $10,482
2014-09-30 $10,557
2014-06-30 $10,934
2014-03-31 $10,264
2013-12-31 $11,320
2013-09-30 $11,032
2013-06-30 $11,010
2013-03-31 $10,671
2012-12-31 $11,737
2012-09-30 $11,488
2012-06-30 $12,311
2012-03-31 $11,731
2011-12-31 $12,294
2011-09-30 $12,022
2011-06-30 $12,151
2011-03-31 $11,580
2010-12-31 $12,094
2010-09-30 $11,125
2010-06-30 $11,346
2010-03-31 $11,422
2009-12-31 $10,093
2009-09-30 $6,050
2009-06-30 $5,900
2009-03-31 $5,385
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $321.544B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.143B 123.75
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Pfizer (PFE) United States $150.148B 14.53
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80